In the HOKUSAI-VTE study, evaluating the direct Factor Xa inhibitor edoxaban in patients with symptomatic DVT and/or PE, a non-inferiority margin of 1.50 has been adopted (clinicaltrials.gov: NCT00986154) [29]. Here, F10 is linked to deep vein thrombosis.